Systematic review with meta-analysis: association between acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) and risk of Crohn's disease and ulcerative colitis exacerbation

被引:67
作者
Moninuola, O. O. [1 ]
Milligan, W. [2 ]
Lochhead, P. [3 ]
Khalili, H. [3 ,4 ,5 ]
机构
[1] Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA 02115 USA
[2] Univ Aberdeen, Aberdeen, Scotland
[3] Massachusetts Gen Hosp, Dept Med, Clin & Translat Epidemiol Unit, Boston, MA 02114 USA
[4] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA
[5] Harvard Med Sch, Boston, MA USA
关键词
INFLAMMATORY-BOWEL-DISEASE; SELECTIVE CYCLOOXYGENASE-2 INHIBITORS; CLINICAL RELAPSE; ASPIRIN; ROFECOXIB; INGESTION; SAFETY; COHORT; FLARES;
D O I
10.1111/apt.14606
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Unlike acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs) have generally been thought to be associated with increased risk of IBD exacerbation. Aim: To carry out a systematic review and meta-analysis of previous studies examining the association between acetaminophen and NSAIDs including cyclooxygenase (COX-2) inhibitors use, and risk of Crohn's disease (CD) and ulcerative colitis (UC) exacerbation. Methods: We identified published manuscripts and abstracts through 1 March 2017 by systematic search of Medline, Embase, Cochrane and other trial registries. Quality assessment was done using Newcastle-Ottawa scale and random-effect meta-analysis using pooled relative risks (RRs) and 95% CIs were calculated. Results: Eighteen publications between years 1983 and 2016 were identified. For the meta-analysis, pooled RRs of disease exacerbation with NSAIDs use were (1.42, 95% CI, 0.65-3.09), I-2=60.3% for CD, and (1.52, 95% CI, 0.87-2.63), I-2=56.1% for UC. The corresponding values for acetaminophen use were (1.40, 95% CI, 0.96-2.04), I-2=45.6% for UC, and (1.56, 95% CI, 1.22-1.99), I-2=0.0% for IBD. Sensitivity analyses limited to studies with low risk of bias showed a significantly increased risk of CD exacerbation (1.53, 95% CI, 1.08-2.16) but not UC (0.94, 95% CI, 0.36-2.42) with NSAIDs use. Conclusions: Contrary to generally accepted belief, we did not find a consistent association between NSAIDs use and risk of CD and UC exacerbation. There was also no consistent evidence for association with acetaminophen although further studies are needed.
引用
收藏
页码:1428 / 1439
页数:12
相关论文
共 53 条
[41]   Relapse of inflammatory bowel disease associated with use of nonsteroidal anti-inflammatory drugs [J].
Meyer, AM ;
Ramzan, NN ;
Heigh, RI ;
Leighton, JA .
DIGESTIVE DISEASES AND SCIENCES, 2006, 51 (01) :168-172
[42]   Review article: cellular and molecular mechanisms of NSAID-induced peptic ulcers [J].
Musumba, C. ;
Pritchard, D. M. ;
Pirmohamed, M. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 30 (06) :517-531
[43]   Identification of Environmental Factors Associated with Inflammatory Bowel Disease in a Southwestern Highland Region of China: A Nested Case-Control Study [J].
Niu, Junkun ;
Miao, Jiarong ;
Tang, Yuan ;
Nan, Qiong ;
Liu, Yan ;
Yang, Gang ;
Dong, Xiangqian ;
Huang, Qi ;
Xia, Shuxian ;
Wang, Kunhua ;
Miao, Yinglei .
PLOS ONE, 2016, 11 (04)
[44]   ANALGESIC INGESTION AND OTHER FACTORS PRECEDING RELAPSE IN ULCERATIVE-COLITIS [J].
RAMPTON, DS ;
MCNEIL, NI ;
SARNER, M .
GUT, 1983, 24 (03) :187-189
[45]   An open-label trial of the selective cyclo-oxygenase-2 inhibitor, rofecoxib, in inflammatory bowel disease-associated peripheral arthritis and arthralgia [J].
Reinisch, W ;
Miehsler, W ;
Dejaco, C ;
Harrer, M ;
Waldhoer, T ;
Lichtenberger, C ;
Vogelsang, H .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (11) :1371-1380
[46]   WHY DO PATIENTS WITH ULCERATIVE-COLITIS RELAPSE [J].
RILEY, SA ;
MANI, V ;
GOODMAN, MJ ;
LUCAS, S .
GUT, 1990, 31 (02) :179-183
[47]   Cumulative Incidence and Risk Factors for Hospitalization and Surgery in a Population-based Cohort of Ulcerative Colitis [J].
Samuel, Sunil ;
Ingle, Steven B. ;
Dhillon, Shamina ;
Yadav, Siddhant ;
Harmsen, W. Scott ;
Zinsmeister, Alan R. ;
Tremaine, William J. ;
Sandborn, William J. ;
Loftus, Edward V., Jr. .
INFLAMMATORY BOWEL DISEASES, 2013, 19 (09) :1858-1866
[48]   Safety of celecoxib in patients with ulcerative colitis in remission: A randomized, placebo-controlled, pilot study [J].
Sandborn, WJ ;
Stenson, WF ;
Brynskov, J ;
Lorenz, RG ;
Steidle, GM ;
Robbins, JL ;
Kent, JD ;
Bloom, BJ .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2006, 4 (02) :203-211
[49]   Clinical course in Crohn's disease: Results of a Norwegian population-based ten-year follow-up study [J].
Solberg, Inger Camilla ;
Vatn, Morten H. ;
Hoie, Ole ;
Stray, Njaal ;
Sauar, Jostein ;
Jahnsen, Jorgen ;
Moum, Bjorn ;
Lygren, Idar .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2007, 5 (12) :1430-1438
[50]   Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage [J].
Sostres, Carlos ;
Gargallo, Carla J. ;
Lanas, Angel .
ARTHRITIS RESEARCH & THERAPY, 2013, 15